In the latest trading session, Gilead Sciences (GILD) closed at $123.18, marking a -1.38% move from the previous day.

Diversified Trust Co raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 24.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,229 shares of the biopharmaceutical company's stock after purchasing an additional 8,422 shares during the period.

Abacus FCF Advisors LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 16.0% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 138,674 shares of the biopharmaceutical company's stock after selling 26,340 shares during the quarter.

Regatta Capital Group LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ: GILD) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 4,062 shares of the biopharmaceutical company's stock, valued at approximately $451,000. Several other hedge funds also recently made

E. Ohman J or Asset Management AB grew its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 516.3% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 324,647 shares of the biopharmaceutical company's stock after acquiring an additional 271,973 shares

Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.

Confluence Investment Management LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 1.7% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 952,946 shares of the biopharmaceutical company's stock after selling 16,861 shares during the

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 12, 2026 beginning at 11:15 a.m. Pacific Time The live webcast can be accessed at investors.gilead.com and the replay will be available for at least 30 days following the presentation. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and.

Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio R.